Article Text

Download PDFPDF
Sulfation patterns of keratan sulfate in different macular corneal dystrophy immunophenotypes using three different probes
  1. T Saito1,
  2. K Nishida2,
  3. J Nakayama3,
  4. T O Akama4,
  5. M N Fukuda4,
  6. K Watanabe1,
  7. A J Quantock5,
  8. N Maeda1,
  9. H Watanabe1,
  10. Y Tano1
  1. 1
    Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
  2. 2
    Department of Ophthalmology, Tohoku University School of Medicine, Sendai, Japan
  3. 3
    Department of Pathology, Shinshu University School of Medicine, Matsumoto, Japan
  4. 4
    Glycobiology Program, Burnham Institute for Medical Research, La Jolla, CA, USA
  5. 5
    School of Optometry and Vision Sciences, Cardiff University, Cardiff, UK
  1. Professor K Nishida, Department of Ophthalmology, Tohoku University School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai, 980-8574, Japan; knishida{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Macular corneal dystrophy (MCD) is subdivided into three immunophenotypes, MCD types I, IA and II, based on the reactivity of serum and corneal tissue to an antibody that recognises sulfated keratan sulfate (KS).1 In MCD type I (MCD-I), antigenic KS is undetectable in both serum and cornea, while in MCD-II it is present at normal or subnormal levels in serum, and is evident immunohistochemically in the corneal stroma. In MCD-IA, antigenic KS is absent from serum and extracellular stromal matrix, but is detected in keratocytes. Mutations of the carbohydrate sulfotransferase gene, CHST6, have been identified as causative for MCD.2 This study investigated the distribution of differentially sulfated KS in cornea in the three main MCD immunophenotypes.

Materials and methods

Serum and postoperative corneal tissue from three unrelated individuals with MCD from …

View Full Text


  • Funding: Thanks to the Sasakawa Foundation for grant support.

  • Competing interests: None.

  • Ethics approval: The Institutional Review Boards of Osaka University Hospital, Ethical Committees of Osaka University Medical School and Shinsha University School of Medicine approved the protocol of this study.

  • Patient consent: Obtained.